Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

704 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.
Zurlo IV, Schino M, Strippoli A, Calegari MA, Cocomazzi A, Cassano A, Pozzo C, Di Salvatore M, Ricci R, Barone C, Bria E, Tortora G, Larocca LM, Basso M, Martini M. Zurlo IV, et al. Among authors: tortora g. Cancer Immunol Immunother. 2022 Jan;71(1):45-55. doi: 10.1007/s00262-021-02960-1. Epub 2021 May 19. Cancer Immunol Immunother. 2022. PMID: 34009410 Free PMC article.
Emerging pathways and future targets for the molecular therapy of pancreatic cancer.
Vaccaro V, Melisi D, Bria E, Cuppone F, Ciuffreda L, Pino MS, Gelibter A, Tortora G, Cognetti F, Milella M. Vaccaro V, et al. Among authors: tortora g. Expert Opin Ther Targets. 2011 Oct;15(10):1183-96. doi: 10.1517/14728222.2011.607438. Epub 2011 Aug 7. Expert Opin Ther Targets. 2011. PMID: 21819318 Review.
Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies.
Loupakis F, Cremolini C, Salvatore L, Schirripa M, Lonardi S, Vaccaro V, Cuppone F, Giannarelli D, Zagonel V, Cognetti F, Tortora G, Falcone A, Bria E. Loupakis F, et al. Among authors: tortora g. Cancer. 2012 Mar 15;118(6):1523-32. doi: 10.1002/cncr.26460. Epub 2011 Aug 25. Cancer. 2012. PMID: 22009364 Free article.
Sorafenib for lung cancer: is the "Battle" still open?
Bria E, Pilotto S, Tortora G. Bria E, et al. Among authors: tortora g. Expert Opin Investig Drugs. 2012 Oct;21(10):1445-8. doi: 10.1517/13543784.2012.707191. Epub 2012 Jul 16. Expert Opin Investig Drugs. 2012. PMID: 22799503
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials.
Pilotto S, Di Maio M, Peretti U, Kinspergher S, Brunelli M, Massari F, Sperduti I, Giannarelli D, De Marinis F, Tortora G, Bria E. Pilotto S, et al. Among authors: tortora g. Crit Rev Oncol Hematol. 2014 May;90(2):135-45. doi: 10.1016/j.critrevonc.2013.11.005. Epub 2013 Dec 1. Crit Rev Oncol Hematol. 2014. PMID: 24332915 Review.
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
Pilotto S, Bria E, Peretti U, Massari F, Garassino M, Pelosi G, Tortora G. Pilotto S, et al. Among authors: tortora g. J Thorac Oncol. 2013 Dec;8(12):e105-6. doi: 10.1097/JTO.0b013e3182a00e37. J Thorac Oncol. 2013. PMID: 24389444 Free article. No abstract available.
704 results